Viking previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers with a BMI ≥30.

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of ...

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I remain bullish on VKTX stock.

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.